Literature DB >> 5762045

The accumulation of guanethidine by human blood platelets.

D J Boullin, R A O'Brien.   

Abstract

1. When human blood platelets were incubated aerobically in plasma containing 2 x 10(-7) to 10(-3)M radioactive guanethidine for 10 min to 6 hr, the drug was accumulated against a concentration gradient until concentration ratios (platelet/plasma) of up to 80:1 were obtained.2. The decline in rate of uptake after 3 hr appeared to result from a decrease in platelet viability, because accumulation was reduced by prolonged incubation before addition of guanethidine.3. Uptake was energy-dependent because it was inhibited by cold and ouabain.4. Sodium ions were essential for guanethidine uptake and retention of 5-hydroxytryptamine (5-HT).5. Accumulation was inhibited by 5-HT, desipramine, cocaine, dexamphetamine, bretylium, tyramine and noradrenaline; bethanidine, p-chlorophenylalanine and (-)-alpha-methyldopa were inactive.6. Guanethidine was tightly bound to platelets, only 10% being lost from labelled cells during 60 min incubation in drug-free plasma; but efflux was increased by addition of amphetamine.7. The binding sites for guanethidine seemed to be different from those for 5-HT since guanethidine accumulation was independent of 5-HT levels, and neither guanethidine uptake or release were affected by reserpine.8. Guanethidine was not metabolized by platelets or plasma in vitro.9. We consider that, if our results regarding uptake, binding and release of guanethidine are confirmed in vivo, and also found to apply to other pharmacologically active agents, then the eventual loss of a platelet-bound substance may increase pharmacological action by raising plasma levels.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5762045      PMCID: PMC1703085          DOI: 10.1111/j.1476-5381.1969.tb07969.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Release of serotonin from blood platelets by reserpine in vitro.

Authors:  A CARLSSON; P A SHORE; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1957-07       Impact factor: 4.030

2.  5-Hydroxytryptamine in normal human platelets.

Authors:  R M HARDISTY; R S STACEY
Journal:  J Physiol       Date:  1955-12-29       Impact factor: 5.182

Review 3.  Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets.

Authors:  A Pletscher
Journal:  Br J Pharmacol Chemother       Date:  1968-01

4.  Effect of drugs and cations on ultrastructure and 5-hydroxytryptamine content of blood platelets.

Authors:  M da Prada; J P Tranzer; A Pletscher
Journal:  J Pharmacol Exp Ther       Date:  1967-12       Impact factor: 4.030

5.  Studies on the distribution and excretion of a metabolite of guanethidine in the rat.

Authors:  C J Furst
Journal:  Br J Pharmacol Chemother       Date:  1968-01

6.  Evidence for intra-cellular guanethidine stores in the fat heart revealed after removal of calcium ions.

Authors:  D J Boullin
Journal:  Br J Pharmacol Chemother       Date:  1968-01

7.  Uptake of amino acids by the human platelet.

Authors:  P D Zieve; H M Solomon
Journal:  Am J Physiol       Date:  1968-01

8.  Accumulation of lipid-insoluble compounds by the human platelet.

Authors:  P D Zieve; H M Solomon
Journal:  Am J Physiol       Date:  1967-11

9.  The accumulation of organic bases by the human platelet.

Authors:  H M Solomon; P D Zieve
Journal:  J Pharmacol Exp Ther       Date:  1967-01       Impact factor: 4.030

10.  The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation.

Authors:  D C Mills; I A Robb; G C Roberts
Journal:  J Physiol       Date:  1968-04       Impact factor: 5.182

View more
  14 in total

1.  Transport of taurine by normal human blood platelets.

Authors:  L Ahtee; D J Boullin; M K Paasonen
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

2.  Abnormalities of 5-hydroxytryptamine uptake and binding by blood platelets from children with Down's syndrome.

Authors:  D J Boullin; R A O'Brien
Journal:  J Physiol       Date:  1971-01       Impact factor: 5.182

3.  The density of sodium pumping sites in mammlian non-myelinated nerve fibres.

Authors:  D Landowne; J M Ritchie
Journal:  J Physiol       Date:  1969-10       Impact factor: 5.182

4.  Uptake and loss of 14 C-dopamine by platelets from children with infantile autism.

Authors:  D J Boullin; R A O'Brien
Journal:  J Autism Child Schizophr       Date:  1972 Jan-Mar

5.  Preliminary report on the incorporation of guanethidine and reserpine into rat peritoneal mast cells in vitro.

Authors:  J Gripenberg; S E Jansson
Journal:  Experientia       Date:  1971-12-15

6.  Peripheral and striatal responses from the substantia nigra and adjacent reticular formation.

Authors:  M J Goswell; E M Sedgwick
Journal:  J Physiol       Date:  1969-07       Impact factor: 5.182

7.  Laboratory predictions of infantile autism based on 5-hydroxytryptamine efflux from blood platelets and their correlation with the Rimland E-2 score.

Authors:  D J Boullin; M Coleman; R A O'Brien; B Rimland
Journal:  J Autism Child Schizophr       Date:  1971 Jan-Mar

8.  Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone.

Authors:  J H Silas; G T Tucker; A J Smith; N R Fieller
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

9.  Differential adriamycin distribution to blood components.

Authors:  T Colombo; M Broggini; S Garattini; M G Donelli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

10.  Accumulation of quinidine by human blood platelets: effects on platelet ultrastructure and 5-hydroxytryptamine.

Authors:  D J Boullin; R A O'Brien
Journal:  Br J Pharmacol       Date:  1971-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.